Philips Trial to Reduce Radiation in Coronary Interventions
Philips Trial to Reduce Radiation in Coronary Interventions
Published: May 20, 2025. Announced at EuroPCR 2025 in Paris.
Key Points:
1. Study Announcement:
Philips announced the RADIQAL trial during the EuroPCR 2025 in Paris.
2. Trial Objective:
To test the feasibility of ultralow X-ray doses during percutaneous coronary interventions (PCI) without compromising image quality.
3. Study Details:
• 824 patients across 6 hospitals
• Countries: Spain, Czech Republic, Denmark, USA
• Multicenter, randomized trial
4. Technology:
The Philips Azurion system is widely used for image guidance for PCIs. It was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
• Cleared in Europe (CE mark, EU MDR)
• Not yet FDA-approved in the U.S.
5. Lead Investigators:
• Dr. Javier Escaned (Madrid, Spain)
• Dr. Darshan Doshi (Massachusetts General Hospital, USA)
6. Clinical Importance:
• Reducing radiation is vital for patients (e.g. high BMI, complex cases) and staff safety.
• The study aims to balance dose reduction with high-quality angiographic imaging, even with diluted contrast.
7. Current Status:
• First patient enrolled in Denmark